Mr James Armitage MD, FRCS (Urol)
James is a Consultant Urological Surgeon at Addenbrooke's hospital where he specialises in the management of patients with Kidney Cancer and Testis Cancer.
James completed his undergraduate medical training at Guys and St Thomas's Hospitals in London and completed his basic surgical training in Chichester. He then undertook a period of research at The Royal College of Surgeons of England that led to the award of MD. James went on to complete his higher surgical training in the East of England during which time he gained specialist experience at both the Norfolk and Norwich, and Addenbrooke's teaching hospitals.
He was recently elected as a member of the Executive Committee of the British Association of Surgeons Section of Oncology. James maintains a strong academic interest, publishing in high quality peer-reviewed clinical journals and presenting his research locally, nationally and internationally.
James is Honorary Senior Lecturer at both the University of Edinburgh and Anglia Ruskin universities where he is a tutor for their Urology Masters degrees. He is a member of the Joint Committee on Intercollegiate Examinations Urology Question Writing panel and is the Urology Specialty Trainee Lead at Addenbrooke’s hospital. He has organised and teaches on national and international training courses on Emergency Urology and laser prostate surgery, and he regularly teaches on the FRCS (Urol) revision course.
Outside work, James is a keen hockey player and golfer, and is kept busy by his three teenage sons.
Mr Thomas Mitchell MEng, DPhil, BMBCh, FRCS (Urol)
Tom is a Cancer Research UK and Royal College of Surgeons Clinician Scientist Fellow Honorary Consultant Urologist.
Tom began his medical training as a graduate in Oxford, prior to rotating through Junior Doctor roles in the Severn Deanery. His formal training in urology started in the East of England, at Addenbrooke's and the West Suffolk Hospital, finishing with the Kidney Cancer Fellowship at Addenbrooke's Hospital. He now works clinically as an Honorary Consultant, supported as a Clinician Scientist Fellow by Cancer Research UK and the Royal College of Surgeons.
Intermixed with his clinical development, he has a wide experience in academic research. This has ranged from formal qualification in Medical Engineering and device development, through to extensive genomic based investigations. focusing on understanding how cancers initiate, progress, and evade treatment.
His clinical interest centres around the surgical management of patients with renal cancer. He is closely involved in the portfolio of the renal oncological clinical trials that are established in Cambridge, using sequencing technologies to better understand the behaviour of these tumours.
Dr Brent O'Carrigan BSc, MBBS, MMed, MRCP(UK), FRACP
Dr O'Carrigan is a Consultant Medical Oncologist at Addenbrooke's. He trained in London and Sydney, Australia, then completed a drug development early phase clinical trials fellowship at the Royal Marsden with Professor Johann de Bono. Dr. O'Carrigan got his PhD at the CRUK Cambridge Institute with Professor Carlos Caldas, with funding from the prestigious General Sir John Monash and Cambridge Trust International Scholarships. For his PhD in translational cancer research, Dr. O'Carrigan profiled the immune response with high-dimensional mass cytometry and the treatment response with ctNDA of patients with cancer.
His clinical interests are renal cancer and melanoma, translational research, drug development, clinical trials and novel trial designs.
Dr. O'Carrigan is a seasoned traveller; he's trekked in the Himalayas, camped in Kenya and Tanzania, scuba dived in Mozambique, and proposed to his now wife in Cambodia.
Professor Evis Sala MD, PhD, FRCR
Evis Sala is the Professor of Oncological Imaging at the University of Cambridge and co-leads the CRUK Cambridge Centre Advanced Cancer Imaging Programme and the Integrated Cancer Medicine Programme.
Professor Sala’s research focuses on the development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging. Her research in the field of radiogenomics has focused on understanding the molecular basis of cancer by demonstrating the phenotypic patterns which occur as a result of multiple genetic alterations that interact with the tumour microenvironment to drive the disease in several tumour types. Her work integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. She is also leading multiple research projects focusing on the development and implementation of artificial intelligence methods for image reconstruction, segmentation, and data integration.
Professor Sala is an outstanding educator, orator and mentor. In recognition for her contribution to education and research in oncological imaging she received the Radiology Society of North America (RSNA) Honoured Educator Award in 2014, 2017 and 2020. Her leadership extends to the most important international bodies in the field, as Fellow of the International Cancer Imaging Society, Fellow of the International Society for Magnetic Resonance in Medicine and Fellow of the European Society of Urogenital Radiology.
Professor Sala played volleyball for the Albanian national under 21s team, she loves Latin dancing and modern art.